Buckeyes - You're saying Hepa may try to negotiate for the rights to Asia that they don't already own? That could make sense. China and the territories represent about a 1.8 billion person market so adding the remainder of Asia could add another billion or so bodies to their potential market. 

The biggest challenge I see is that today Hepa is more of a B to B business and starting a distribution model in their existing territories will have its own challenges and capital requirements.

A partnership with a BP that doesn't already have distribution in Hepa's existing territories may be the best scenario we could ask for. That BP would not only get sales milestones on apabetalone but could potentially get distribution of their existing products in an expanded market. 

I think we need to have Toinv or others in the distribution world weigh in on this.

tada